Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR034
MIFTS: 38

Ovarian Clear Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards integrated aliases for Ovarian Clear Cell Adenocarcinoma:

IMPROVED
Name: Ovarian Clear Cell Adenocarcinoma 11 14 16 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:5304
NCIt 49 C40078
SNOMED-CT 68 763131005
UMLS 71 C1518693
Sources

Summaries for Ovarian Clear Cell Adenocarcinoma

About this section

Disease Ontology: 11 A ovarian adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary: Ovarian Clear Cell Adenocarcinoma is related to clear cell adenocarcinoma and clear cell adenofibroma. An important gene associated with Ovarian Clear Cell Adenocarcinoma is PPM1D (Protein Phosphatase, Mg2+/Mn2+ Dependent 1D), and among its related pathways/superpathways are DNA Damage and NF-kappaB Pathway. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and cervix, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)
Sources

Related Diseases for Ovarian Clear Cell Adenocarcinoma

About this section

Diseases related to Ovarian Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 31.8 TP53 HNF1B ARID1A
2 clear cell adenofibroma 30.8 PIK3CA ARID1A
3 ovary adenocarcinoma 30.7 TP53 PIK3CA H2AC18 ESS2 ARID1A
4 serous cystadenocarcinoma 30.6 TP53 PIK3CA HNF1B H2AC18 ESS2 ARID1A
5 endometriosis of ovary 30.3 PIK3CA HNF1B ARID1A
6 ovarian clear cell carcinoma 30.2 TP53 PIK3CA HNF1B H2AC18 ESS2 ARID1A
7 ovarian serous cystadenocarcinoma 30.2 TP53 PIK3CA H2AC18
8 wilms tumor 1 29.9 WT1-AS TP53 H2AC18 CHEK2
9 clear cell adenocarcinoma of the ovary 11.6
10 adenocarcinoma 10.9
11 ovarian cancer 10.8
12 endometriosis 10.7
13 appendix adenocarcinoma 10.5
14 ovarian epithelial cancer 10.5
15 mucinous adenocarcinoma 10.5
16 epithelial-myoepithelial carcinoma 10.4
17 hypercalcemia, infantile, 1 10.3
18 adenofibroma 10.3
19 ovarian small cell carcinoma 10.2 H2AC18 ARID1A
20 small-cell carcinoma of the ovary of hypercalcemic type 10.2 TP53 ARID1A
21 histone mutated tumor 10.2 TP53 PPM1D H2AC18
22 esophagus verrucous carcinoma 10.2 TP53 PIK3CA
23 vaginal carcinosarcoma 10.2 TP53 PIK3CA
24 bartholin's gland adenoid cystic carcinoma 10.2 PIK3CA ARID1A
25 fallopian tube endometrioid adenocarcinoma 10.2 HNF1B ARID1A
26 cowden syndrome 5 10.2 PIK3CA H2AC18
27 renal cell carcinoma, nonpapillary 10.2
28 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 10.2
29 47 xxx syndrome 10.2
30 malignant epithelial tumor of ovary 10.2
31 rhabdoid cancer 10.2 TP53 H2AC18 ARID1A
32 penile benign neoplasm 10.2 TP53 PIK3CA
33 intrahepatic cholangiocarcinoma 10.2 TP53 H2AC18 ARID1A
34 lung oat cell carcinoma 10.2 TP53 PIK3CA
35 anal squamous cell carcinoma 10.2 TP53 PIK3CA H2AC18
36 anus cancer 10.1 TP53 PIK3CA H2AC18
37 anus disease 10.1 TP53 PIK3CA H2AC18
38 hereditary breast cancer 10.1 PPM1D CHEK2
39 rectal disease 10.1 TP53 PIK3CA H2AC18
40 tonsil cancer 10.1 TP53 PIK3CA H2AC18
41 estrogen-receptor positive breast cancer 10.1 TP53 PIK3CA H2AC18
42 female reproductive endometrioid cancer 10.1 TP53 PIK3CA ARID1A
43 apocrine adenocarcinoma 10.1 TP53 PIK3CA
44 endometrial serous adenocarcinoma 10.1 TP53 PIK3CA ARID1A
45 mismatch repair cancer syndrome 10.1 TP53 PIK3CA ARID1A
46 familial ovarian cancer 10.1 TP53 CHEK2
47 oropharynx cancer 10.1 TP53 PIK3CA H2AC18
48 pre-malignant neoplasm 10.1 TP53 PIK3CA H2AC18
49 uterine benign neoplasm 10.1 TP53 PIK3CA ARID1A
50 endocervical adenocarcinoma 10.1 TP53 PIK3CA ARID1A

Graphical network of the top 20 diseases related to Ovarian Clear Cell Adenocarcinoma:



Diseases related to Ovarian Clear Cell Adenocarcinoma
Sources

Symptoms & Phenotypes for Ovarian Clear Cell Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.02 CHEK2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.02 CHEK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.02 CHEK2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.02 CHEK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.02 CHEK1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 CHEK1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.02 CHEK2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.02 PPP1R16A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.02 CHEK1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.02 CHEK1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.02 CHEK2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.02 CHEK1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.02 CHEK1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.02 CHEK1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.02 CHEK1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.02 CHEK1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.02 CHEK1 CHEK2 PIK3CA PPP1R16A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.02 CHEK1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.02 CHEK1 CHEK2
20 Decreased viability in pancreas lineage GR00235-A 9.33 ARID1A CHEK2 TP53
21 Increased CDKN1A mRNA expression GR00389-S-1 8.32 CHEK1

MGI Mouse Phenotypes related to Ovarian Clear Cell Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.28 ARID1A CBX7 CHEK1 CHEK2 NEU3 PIK3CA
Sources

Drugs & Therapeutics for Ovarian Clear Cell Adenocarcinoma

About this section

Drugs for Ovarian Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
4
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
5
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
6
Olaparib Approved Phase 3 763113-22-0 23725625
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
10
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
11
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
12
Cediranib Investigational Phase 3 288383-20-0 9933475
13
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
14
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
15 Micronutrients Phase 3
16 Carotenoids Phase 3
17 Trace Elements Phase 3
18 Antineoplastic Agents, Immunological Phase 3
19 Liposomal doxorubicin Phase 2, Phase 3
20 Tubulin Modulators Phase 3
21 Protein Kinase Inhibitors Phase 3
22 Antimitotic Agents Phase 3
23 topoisomerase I inhibitors Phase 2, Phase 3
24 Antibodies, Monoclonal Phase 3
25 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
26 Antibiotics, Antitubercular Phase 2, Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3
28 Immunologic Factors Phase 3
29 Albumin-Bound Paclitaxel Phase 3
30 Immunoglobulins, Intravenous Phase 3
31 Immunoglobulin G Phase 3
32 Mitogens Phase 3
33 Angiogenesis Inhibitors Phase 3
34 Endothelial Growth Factors Phase 3
35 Taxane Phase 3 108169
36 Antiviral Agents Phase 3
37 Anti-Infective Agents Phase 3
38 Antimetabolites Phase 3
39 Immunosuppressive Agents Phase 3
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
42
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
43
Durvalumab Approved, Investigational Phase 2 1428935-60-7
44
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
45
Nivolumab Approved Phase 2 946414-94-4
46
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
47 Antineoplastic Agents, Alkylating Phase 2
48 Antirheumatic Agents Phase 2
49 Alkylating Agents Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
5 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
8 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
9 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
10 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
11 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
12 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
13 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
14 A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
15 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
16 EON: A Single-Arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Recruiting NCT05026606 Phase 2
17 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
18 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
19 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Active, not recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
20 A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Active, not recruiting NCT03348631 Phase 2 Tazemetostat
21 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
22 A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
23 Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer Not yet recruiting NCT05231122 Phase 2
24 Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion Not yet recruiting NCT04919629 Phase 2
25 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
26 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
27 A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors Recruiting NCT05039801 Phase 1 Glutaminase Inhibitor IPN60090
28 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
29 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Recruiting NCT04092270 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
30 First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours Not yet recruiting NCT05498597 Phase 1 AMT-151
31 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Terminated NCT03924245 Phase 1 Entinostat;Olaparib
32 Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients Completed NCT02129036
33 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Completed NCT01504126 Early Phase 1 Chemotherapy;Propranolol Hydrochloride
34 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Terminated NCT03641287

Search NIH Clinical Center for Ovarian Clear Cell Adenocarcinoma

Sources

Genetic Tests for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Anatomical Context for Ovarian Clear Cell Adenocarcinoma

About this section

Organs/tissues related to Ovarian Clear Cell Adenocarcinoma:

MalaCards : Ovary, Endothelial, Cervix, Kidney, Liver, Skin
Sources

Publications for Ovarian Clear Cell Adenocarcinoma

About this section

Articles related to Ovarian Clear Cell Adenocarcinoma:

(show top 50) (show all 144)
# Title Authors PMID Year
1
Synchronous primary malignancies in ovarian cancer and liver angiosarcoma. 62
36217325 2022
2
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. 62
35658326 2022
3
Immunochemical analysis of iron transporters and M2 macrophages in ovarian endometrioma and clear cell adenocarcinoma. 62
34194738 2021
4
Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer. 62
32917727 2020
5
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). 62
32591370 2020
6
Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. 62
32316112 2020
7
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. 62
29979406 2018
8
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. 62
29933751 2018
9
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. 62
29184869 2017
10
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. 62
27660815 2016
11
Rare and challenging case of stroke as a manifestation of non bacterial thrombotic endocarditis in an underlying ovarian clear cell carcinoma. 62
27833758 2016
12
[Ovarian Cancer Rupture Causing Acute Abdomen That Required Emergency Surgery - A Case Report]. 62
28133347 2016
13
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. 62
27699033 2016
14
Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. 62
27120812 2016
15
ARID1A gene mutation in ovarian and endometrial cancers (Review). 62
26572704 2016
16
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. 62
26397155 2015
17
The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma. 62
25855053 2015
18
Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review. 62
26622893 2015
19
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. 62
25398420 2015
20
[A Case of Pneumocystis Pneumonia during Chemotherapy for Recurrent Ovarian Cancer]. 62
26197755 2015
21
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. 62
24721826 2015
22
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. 62
25658832 2015
23
Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. 62
25755836 2015
24
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. 62
26082939 2014
25
Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. 62
25083560 2014
26
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy]. 62
25434451 2014
27
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. 62
25275661 2014
28
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. 62
24306200 2014
29
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. 62
24987918 2014
30
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. 62
24375438 2014
31
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. 62
24707459 2014
32
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. 62
24815386 2014
33
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. 62
24669262 2014
34
Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. 62
24459582 2014
35
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. 62
24504419 2014
36
[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin]. 62
24196084 2013
37
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. 62
23805888 2013
38
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. 62
23899586 2013
39
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. 62
23430509 2013
40
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. 62
23726144 2013
41
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. 62
23502469 2013
42
Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. 62
23819061 2013
43
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. 62
24244679 2013
44
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. 62
23469222 2013
45
Clear cell carcinoma of the female genital tract (not everything is as clear as it seems). 62
22885379 2012
46
[Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors]. 62
23159083 2012
47
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. 62
22871047 2012
48
[DNA damage response in ovarian clear cell adenocarcinoma]. 62
22812231 2012
49
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. 62
22498943 2012
50
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. 62
22317866 2012
Sources

Variations for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Expression for Ovarian Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Clear Cell Adenocarcinoma.
Sources

Pathways for Ovarian Clear Cell Adenocarcinoma

About this section

Pathways related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
DNA Damage 3
12.31 TP53 PPM1D CHEK2 CHEK1
2
NF-kappaB Pathway 70
Show member pathways
 12.21 TP53 PIK3CA CHEK2 CHEK1
3
DNA IR-double strand breaks and cellular response via ATM 74
Show member pathways
 11.69 TP53 CHEK2 CHEK1
4
Retinoblastoma gene in cancer 74
11.62 TP53 STMN1 CHEK1
5
BRCA1 Pathway 64
Show member pathways
 11.57 TP53 CHEK2 CHEK1
6
ATM Pathway 64
Show member pathways
 11.55 TP53 CHEK2 CHEK1
7
Pathways affected in adenoid cystic carcinoma 74
11.4 ARID1A PIK3CA TP53
8
Cell cycle Role of 14-3-3 proteins in cell cycle regulation 22
Show member pathways
 11.2 TP53 CHEK2 CHEK1
9
DNA IR-damage and cellular response via ATR 74
11.17 TP53 PPM1D CHEK2 CHEK1
10
ATM signaling in development and disease 74
11.15 PPM1D CHEK2 CHEK1
11
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.08 TP53 CHEK2 CHEK1
12
Integrated cancer pathway 74
10.91 TP53 CHEK2 CHEK1
13
p53 pathway 61
10.62 TP53 PPM1D CHEK2 CHEK1
14
PLK3 signaling events 61
10.18 TP53 CHEK2
Sources

GO Terms for Ovarian Clear Cell Adenocarcinoma

About this section

Biological processes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G2/M transition of mitotic cell cycle GO:0000086 9.73 PPM1D CHEK2 CHEK1
2 signal transduction in response to DNA damage GO:0006975 9.55 CHEK2 CHEK1
3 signal transduction in response to DNA damage GO:0042770 9.55 CHEK2 CHEK1
4 transcription initiation-coupled chromatin remodeling GO:0045815 9.43 TP53 CHEK1 ARID1A
5 replicative senescence GO:0090399 9.1 TP53 CHEK2 CHEK1
Sources

Sources for Ovarian Clear Cell Adenocarcinoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....